340 CCP+ persons without followed for 1047 PYrs = 21.5% developed RA. Risk of RA progression increased w/ CCP level. 46.0% of high level CCP patients progressedto RA by 5 years. High vs low CCP were 5 times more likely to get RA (HR 4.83, 95%CI 2.51-9.31). https://t.co/V3cRnMzerw

QD Clinic - Give them an inch... Patients with the urge to change their meds | RheumNow - https://t.co/GZfy9HJ55q

Claims data analysis of 11,248 matched patients starting abatacept or TNFi showed the risk of hospitalized infection was 37 ABA vs 47 TNFi (HR 0.78; 95% CI 0.64-0.95). Thus ABA was associated with a 22% less risk any hospitalized infection. https://t.co/Ij6b0IYcAZ

A cross-sectional study included 1276 RA outpatients showed the prevalence of dysfunctional LBP was 32.8%. Risk factors include BMI (OR 1.116; P < 0.001), onset age, disease duration of RA, MTX use, vertebral Fx, facet erosion, DAS-28CRP, pelvic tilt https://t.co/tg8cRImHdM

QD Clinic - Smoking & RA | RheumNow - Smoking ignites, worsens RA. How to stop smoking. https://t.co/1K1Lal8KRB

QD Clinic - Pushing to LDAS or Remission | RheumNow - Great response in PsA, but is it enough? https://t.co/K7q4NrSOrN

QD Clinic - Medication Reminders | RheumNow -Measures taken to remind or ensure medication compliance https://t.co/7xnuGPeFxI

THe gender gap has decreased from 2017 to now by nearly $15k ($105,000 to a $90,490 difference between female and male physicians) with less difference in Birmingham, Bridgeport, Milwaukee, jacksonville but more in Louisville, N.Orleans, Austin & Dallas. https://t.co/U7xjJHPd0O

2019 Doximity report shows Rheumatologists are the 14th lowest paid of all medical specialties; but is amongst the lowest with a gender gap difference. check it out here https://t.co/j3YOybQ78n

Murine BM–derived macrophages or human monocytes treated w/ tofacitinib or selective JAK1, JAK3 inhibitors. Both TOFA & JAK1i but not JAK3i effectively inhibited STAT1 phosphorylation & IFN gamma production, suggesting affects on macrophage function. https://t.co/qILxzCDrCH

Boehringer Ingelheim announce s FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD https://t.co/BQz94Kg4Px